Status:
RECRUITING
Effect of IMO on Intestinal Microbiota Translocation in Cirrhosis
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Decompensated Cirrhosis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis. The main questio...
Eligibility Criteria
Inclusion
- Age from 18-75.
- Cirrhotic patients.
- Decompensation event: ascites.
- LPS\>0.45EU/ml.
Exclusion
- Pregnant or breast-feeding.
- Active bacterial or fungal infection.
- Other decompensations: Hepatic encephalopathy, gastroesophageal varices and hemorrhage.
- Diagnosis of EASL-ACLF.
- Diarrhea.
- Malignancy.
- Anticipated short survival time.
- Adverse reactions or allergies to oral carbohydrate preparations.
- Substance abuse or addiction.
- Severe extrahepatic diseases (e.g. patients with CKD-5 stage, severe cardiopulmonary dysfunction, and psychiatric disorders).
- Be immunosuppressed or immunodeficient states and the use of immunoglobulins or other immune-boosting conditions.
- Be unsuitable for participating in this trial.
- Participated in any drug trial within the past month
- History of antibacterial or fungal use within 1 week prior to screening
Key Trial Info
Start Date :
November 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2024
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06134544
Start Date
November 25 2023
End Date
July 1 2024
Last Update
April 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital
Guangzhou, Guangdong, China